Company History

Ongoing

Construction continues on expansion of lab facilities.

October 2007

Dr. Fujii invited to speak at the Western Regional Meeting of the ACS.

July 2007

NIAID grant to evaluate selected Aspergillus antigens as potential candidates for vaccine development pending.

Presentation of HSV2 findings at the 2007 American Society of Virology Annual Meeting.

NCI grant to explore feasibility of commercial manufacturing methods for breast cancer therapeutic funded.

Dr. Fujii invited to share status of current projects with BARDA.

November 2001

Registered Trademark for VesiVax.

August 2001

Phase I SBIR grant awarded for developing a targeted leukemia delivery system.

July 2001

Phase I STTR grant awarded to provide anticancer formulations through a subcontract with a biotechnology company.

SCORE grant awarded in collaboration with California State Polytechnic University Pomona for HSV-2 vaccine technology development.

May 2001

Vaccine presentations at the American Society of Microbiology General Meeting in Orlando, Florida.

April 2001

Invited to give oral presentations at the 4th annual Vaccine Research Conference in Arlington, Virginia.

September 2000

Winner of a California Technology Investment Partnership (CalTIP) award ($50,000).

July 2000

California Breast Cancer Research Program grant awarded in collaboration with USC.

April 2000

Phase I SBIR grant awarded for utilizing Molecular GPS to target cancer cells in a targeted liposome system.

Presentation at the Liposome Research Days Conference.

September 1999

Patent application covering the vaccine technology filed.

August 1999

Winner of a California Technology Investment Partnership (CalTIP) award ($150,000).

March 1999

Phase I SBIR grant awarded for developing an Influenza vaccine.

September 1998

Presentation of the initial vaccine results at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

August 1998

Phase I SBIR grant awarded for developing an HIV vaccine.

June 1998

Phase I SBIR grant awarded for developing an HSV2 vaccine.

April 1996

Molecular Express founded.